The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …

Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia
(CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case …

Five-year survival has increased for many hematologic malignancies in the 21st century.
However, whether this has translated into greater long-term survival is unknown. Here, we …

Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia
(CML) are: avoid progression to accelerated phase or blast crisis CML such that patients …

The classical myeloproliferative neoplasms (MPNs), specifically chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …

Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the
real world is limited. In this retrospective study, we examined the survival outcomes and …

There is currently no biomarker that reliably predicts treatment‐free remission (TFR) in
chronic myeloid leukaemia (CML). We characterised effector and suppressor immune …

Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic
phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) …

1St James's University Hospital, Leeds, 2Imperial College, London, 3University of
Southampton, Southampton, 4University Hospital, Nottingham, 5University Hospital of …